38 completed, 6 unknown, 4 recruiting, 4 terminated. 26 Phase 2, 19 Phase 1, 4 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow dacomitinib: new trials by email Literature Review of dacomitinib trials Research Report on dacomitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. lorlatinib, crizotinib, brigatinib - Non-Small Cell Lung Cancer | Completed | Pfizer | 5279 | 2023-06-23 | 2025-03-30 | |
| First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations Dacomitinib+Anlotinib, Dacomitinib - Non-Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Recruiting | Shanghai Chest Hospital | 140 | 2022-10-13 | 2023-04-19 |
| EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study Afatinib/Dacomitinib, Osimertinib - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Region Skane | 200 | 2022-09-21 | 2026-05-14 |
| Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers Oral Dacomitinib - Advanced Solid Tumours, Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | National Cancer Centre, Singapore | 24 | 2021-08-24 | 2025-06-11 |
| Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review Dacomitinib - Lung Cancer | Completed | Pfizer | 307 | 2021-06-11 | 2025-05-31 | |
| Korea Post Marketing Surveillance (PMS) Study of Vizimpro Vizimpro - Lung Neoplasms | Completed | Pfizer | 188 | 2021-03-07 | 2026-02-10 | |
| Dacomitinib in Lung Cancer With Uncommon EGFR Mutations Dacomitinib - Non-small Cell Lung Cancer Metastatic, EGF-R Positive Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | Shanghai Chest Hospital | 30 | 2020-12-08 | 2025-09-08 |
| Central Nervous System(CNS) Efficacy of Dacomitinib Dacomitinib - Non Small Cell Lung Cancer, Brain Metastases | Phase 2 | Unknown | Samsung Medical Center | 30 | 2020-12-07 | 2021-01-05 |
| Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study Bevacizumab, Erlotinib, Gefitinib - NSCLC | Unknown | Guangdong Association of Clinical Trials | 272 | 2020-10-07 | 2020-10-20 | |
| Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC Dacomitinib - EGFR Activating Mutation, NSCLC Stage IV | Unknown | Peking Union Medical College | 82 | 2020-09-01 | 2021-02-24 | |
| Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations Dacomitinib - Metastatic Non Small Cell Lung Cancer | Phase 4 | Completed | Pfizer | 101 | 2020-08-27 | 2024-04-05 |
| PLATFORM Study of Precision Medicine for Rare Tumors Almonertinib 110 MG, Dacomitinib 45 MG, Alectinib 150 MG - Rare Tumor | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 770 | 2020-08-15 | 2025-02-11 |
| An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Dacomitinib - Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases | Phase 2 | Unknown | Guangdong Association of Clinical Trials | 50 | 2020-08-01 | 2020-04-09 |
| Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations Osimertinib, Dacomitinib - NSCLC | Phase 2 | Unknown | Fondazione Ricerca Traslazionale | 170 | 2020-06-12 | 2023-02-21 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice) dacomitinib hydrate - EGFR Mutation-positive Inoperable or Reccrent NSCLC | Completed | Pfizer | 40 | 2020-01-24 | 2026-06-11 | |
| Phase 2 Study of Dacomitinib in NSCLC Dacomitinib - NSCLC Stage IIIB, NSCLC Stage IIIC | Phase 2 | Active not recruiting | National Cancer Centre, Singapore | 118 | 2019-09-11 | 2025-06-12 |
| Evaluate Severe Hepatic Impairment on Dacomitinib PK Dacomitinib - Severe Hepatic Impairment | Phase 1 | Completed | Pfizer | 16 | 2019-04-05 | 2020-11-06 |
| Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer Dacomitinib, Osimertinib - Metastatic Non-small Cell Lung Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 22 | 2019-01-17 | 2025-12-23 |
| A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. Dacomitinib, Osimertinib - EGFR Gene Mutation, Lung Cancer | Early Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 17 | 2018-11-21 | 2025-05-15 |
Showing 20 of 55. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (22) · Neoplasm Metastasis (6) · Lung Neoplasms (5) · Carcinoma, Squamous Cell (4) · Neoplasms (4) · Brain Neoplasms (3) · Recurrence (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma (2) · Glioblastoma (2) · Head and Neck Neoplasms (2) · Anemia (1) · Blast Crisis (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1)
Pfizer (27) · University Health Network, Toronto (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Guangdong Association of Clinical Trials (2) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Centre, Singapore (2) · Shanghai Chest Hospital (2) · The Netherlands Cancer Institute (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Central European Cooperative Oncology Group (1) · David Piccioni, M.D., Ph.D (1) · Fondazione Ricerca Traslazionale (1) · Grupo Español de Investigación en Neurooncología (1) · Massachusetts General Hospital (1) · NCIC Clinical Trials Group (1)
United States (20) · South Korea (13) · China (9) · Canada (7) · Italy (6) · Japan (6) · Spain (6) · Hong Kong (4) · United Kingdom (4) · Australia (3) · India (3) · Netherlands (3) · Poland (3) · Singapore (3) · Taiwan (3)
Alessandro Morabito, MD (1) · Andrea Necchi, MD (1) · Boon Cher Goh (1) · Byoung Chul Cho, M.D.,Ph.D. (1) · Christoph C Zielinski, Univ. Prof. (1) · Daniel SW Tan (1) · Daniel Tan, BSc, MBBS, PhD (1) · David Piccioni, M.D., Ph.D. (1) · E.E. Voest, prof. (1) · Helen Yu, MD (1) · Helena Yu, MD (1) · Junling Li, MD (1)
PMID 26768165, PMID 35195881, PMID 21220471, PMID 22249430, PMID 24501009, PMID 25057165, PMID 25439691, PMID 25439692, PMID 25456362, PMID 25521398, PMID 25899785, PMID 25937431, PMID 26048096, PMID 26581547, PMID 26889973, PMID 28958502, PMID 29191595, PMID 29864379, PMID 31050691, PMID 31313942, PMID 31858327, PMID 32147669, PMID 33331989, PMID 33721611, PMID 34083331, PMID 34120312, PMID 34140482, PMID 35086719, PMID 35305596, PMID 35598186, PMID 36335217, PMID 36870947, PMID 37424386, PMID 38630551, PMID 39360943, PMID 39863139, PMID 40811939, PMID 41365111, PMID 41986720, PMID 42126170
2005 (1), 2008 (1)